Psychometric Evaluation of the Montreal Cognitive Assessment (MoCA) in Three Diverse Samples
Psychometric Evaluation of the Montreal Cognitive Assessment (MoCA) in Three Diverse Samples
复制标题
DOI：
10.1080/13854046.2010.533196
复制
发表时间：
2011-01-01
影响因子：
3.9
通讯作者：
DeFina, Laura F.
中科院分区：
文献类型：
--
作者：
Bernstein, Ira H.;Lacritz, Laura;DeFina, Laura F.
我们的目的是评估蒙特利尔认知评估（莫卡）在非临床和临床人群中的效用。莫卡是一种广泛用于临床老年实践的工具，用于检测和量化认知障碍，对三个不同的样本进行管理，以评估该仪器的心理测量特性。参与者包括库珀中心纵向研究（CCLS）中的482名健康人，达拉斯心脏研究（DHS）评估的1923名健康志愿者，达拉斯县居民的基于人群的样本和69名已知或疑似脑病理的人，用于临床评估。CCLS和DHS组的标准差较小（2.81，3.87），临床组的标准差中等（5.22）。相应的原始系数α分别为0.50、0.63和0.75。因此，变异性和内部一致性是相关的。莫卡评分通常与性别无关，仅在临床组中与年龄相关。然而，在所有三个样本中，莫卡分数和教育之间存在中等程度的正相关。莫卡的可靠性在两个非临床组中极低，但在临床组中很高。尽管莫卡在大型非临床研究中很有用，但它最适合检测和量化临床患者的认知障碍。
Our objective was to evaluate the utility of the Montreal Cognitive Assessment (MoCA) in both non-clinical and clinical populations. The MoCA, a tool used widely in clinical geriatric practice to detect and quantify cognitive impairment, was administered to three diverse samples to assess the psychometric properties of the instrument. Participants were 482 healthy persons seen in the Cooper Center Longitudinal Study (CCLS), 1923 healthy volunteers evaluated by the Dallas Heart Study (DHS), a population-based sample of Dallas County residents and 69 persons with known or suspected brain pathology, seen for clinical evaluation. The standard deviations in the CCLS and DHS groups were small (2.81, 3.87) and moderate in the clinical group (5.22). The corresponding raw coefficients alpha were .50, .63, and .75. Thus, variability and internal consistency were associated. MoCA scores generally did not correlate with gender and correlated with age only in the clinical group. However, there were moderately strong positive correlations between MoCA scores and education in all three samples. The reliability of the MoCA was extremely low in the two non-clinical groups, but was high in the clinical group. Although useful in large non-clinical studies, the MoCA is best suited to detect and quantify cognitive impairment in clinical patients.